The critical fault of IGF1R inhibitor is the lack of a predictive biomarker such as ERBB2-positive breast cancer for trastuzumab or ALK-fusion protein-driven NSCLC for crizotinib. The gene discussed is ALK; the disease is breast carcinoma.